11-16-15 $CTIX ~ Cellceutix Corp. Due Diligence Report

New Post Public Reply Private Reply Replies (0) Message Board
TheHound
11-16-15 $CTIX ~ Cellceutix Corp. Due Diligence Report




$CTIX recent news


Press releases from Cellceutix:

http://cellceutix.com/category/press-release/...r967e.dpbs


PR's from Yahoo:

Mon, 16 Nov 2015 12:30:00 GMT ~ Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based ...

read full: http://finance.yahoo.com/news/cellceutix-sele...00636.html

Wed, 11 Nov 2015 15:34:21 GMT ~ Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to report that ...

read full: http://finance.yahoo.com/news/cellceutix-comp...21863.html


Tue, 10 Nov 2015 15:51:02 GMT ~ Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report ...

read full: http://finance.yahoo.com/news/cellceutix-file...02882.html


Mon, 09 Nov 2015 21:13:18 GMT ~ CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report

read full: http://biz.yahoo.com/e/151109/ctix10-q.html


Tue, 03 Nov 2015 22:26:56 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statem

read full: http://biz.yahoo.com/e/151103/ctix8-k.html


Fri, 30 Oct 2015 17:00:10 GMT ~ Cellceutix aims for late-stage trial of antibiotic next year

read full: http://www.bizjournals.com/boston/blog/biofla...?ana=yahoo


Fri, 30 Oct 2015 12:17:00 GMT ~ How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked ...

read full: http://finance.yahoo.com/news/plays-research-...00619.html


Fri, 30 Oct 2015 11:30:00 GMT ~ Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update ...

read full: http://finance.yahoo.com/news/cellceutix-prov...00865.html


Mon, 26 Oct 2015 12:34:00 GMT ~ Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (OTCMKTS: CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, ...

read full: http://finance.yahoo.com/news/cellceutix-due-...00041.html


Mon, 26 Oct 2015 11:40:04 GMT ~ Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders ...

read full: http://finance.yahoo.com/news/cellceutix-requ...04556.html


Thu, 22 Oct 2015 18:28:15 GMT ~ Cellceutix Responds to Rosen Law Firm

[Marketwired] - Cellceutix Corporation , Cellceutix was created to tackle some of the worst diseases known to man. We are a company that firmly believes in the strength of our science and technology. It is our science ...

read full: http://finance.yahoo.com/news/cellceutix-resp...15404.html


$CTIX filings - Perhaps the most important section.

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany



basic chart ## source: stockscores.com





$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

## source: Opinion summary from various sources.

Additional $CTIX company information:

Business Description: Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. This trial just completed its final cohort. Plans for a Ph 2/3 Ovarian Cancer Study are underway. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is currently conducting a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, recently completed a successful Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Plans for a phase 3 trial are underway w/ FDA's approval. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Please click on the below link to find for more information on completed and active Human Clinical Trials.


https://www.clinicaltrials.gov/ct2/results?te...rch=Search




$CTIX share structure

## source: otcmarkets.com

Market Value: $153,621,697 a/o Nov 10, 2015
Shares Outstanding: 118,170,536 a/o Aug 26, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001



$CTIX extra dd links

Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com

## STOCK DETAILS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CTIX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CTIX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CTIX+Industry

## COMPANY NEWS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/news - http://finance.yahoo.com/q/h?s=CTIX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CTIX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CTIX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CTIX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cellceutix+Corp.&a...ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&am...eutix+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results...=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cellceutix.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cellceutix.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cellceutix.com

## FUNDAMENTALS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/compa...yword/CTIX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/financials?...-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?...rch=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CTIX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CTIX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CTIX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CTIX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CTIX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CTIX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CTIX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CTIX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CTIX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CTIX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CTIX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/st...icker=CTIX



1) UPCOMING MILESTONES / CATALYSTS

SCIENCE:

- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)

OPERATIONS:

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

2) CURRENT TRIALS:

Clinical Trials

Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

3. K (Phase 1, Not recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4

4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations:

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
http://www.cellceutix.com

**This section courtesy of Slcimmuno - Thanks brother!**

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MetroScape: Local Roots Fuel Bold DFW Growth Plans

Updated Category News Views 65

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...

Continue Reading
Ozelle's O-Cyte 1: Revolutionizing Hematology with AI

Updated Category News Views 85

O-Cyte 1 Leads the Charge at MEDICA 2026 With all the chatter floating around the latest whiz-bang healthcare technology, it's downright refreshing to stumble upon something as genuinely promising as Ozelle's O-Cyte 1. Slated to be the talk of the town at this year’s MEDICA in DÜSSELDORF, this shiny new automated hematology analyzer promises to marry the best of AI and...

Continue Reading
UPM Defies Market Challenges: Strong Q3 Cash Flow

Updated Category News Views 102

UPM's Impressive Q3 Performance Amidst Challenges UPM-Kymmene Corporation just dropped their Q3 numbers, and let me tell ya, there's a lot to digest. In the face of some pretty gnarly market conditions—think destocking and those pesky cost inflations—they've managed to pull a rabbit out of the hat with strong cash flow. That's not a small feat, folks; it's a damn...

Continue Reading
2021 Ferrari Portofino Shines Bright at Jake's Motorcars

Updated Category News Views 67

San Diego might be known for its sunny weather, but Jake's Motorcars just cranked the heat with a 2021 Ferrari Portofino that flaunts a special-ordered Mandarin Orange interior. Now, if that doesn't scream "look at me," I don't know what does. For those who aren't just dabbling in Ferraris but are downright obsessed, let's dig into what makes this sports car not just...

Continue Reading
Greek-Serbian Heads Meet to Prep for 2027 Tourism Expo

Updated Category News Views 73

Breaking Cultural and Business Barriers You ever get that feeling when two neighbors finally decide to have a proper sit-down and hash things out? That's the vibe in Athens today, as Greek and Serbian movers and shakers are gathering to lay the groundwork for EXPO 2027 Belgrade. It's a match that's kinda hard to ignore if you're watching Europe's trade routes—especially...

Continue Reading
Royce Micro-Cap Trust: Navigating Small-Cap Waves

Updated Category News Views 6

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Continue Reading
Ryde Group Faces Class Action: Key Investor Takeaways

Updated Category News Views 22

Ryde Group's Tumble: More Than Just Market Volatility When RYDE shares nosedived like a lead balloon, it wasn't due to a market hiccup—it was a darn mess fueled by alleged manipulation. At the heart of this crash are accusations of a blatant pump-and-dump scheme that allegedly swindled investors out of millions. Pump-and-Dump: The Dirty Mechanics This ain't your regular...

Continue Reading
White House Photographer Reveals Unseen Historic Moments

Updated Category News Views 16

You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...

Continue Reading
Ad Council Expands Board, Taps Meta Exec as Vice Chair

Updated Category News Views 203

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Continue Reading
Medunik USA Ensures Steady Supply of Pheburane Amid Changes

Updated Category News Views 39

There's a breath of relief in the air over at Medunik USA, where they're keeping a steady course amidst some choppy waters. Those dealing with urea cycle disorders (UCD) have had their fair share of ups and downs, but Pheburane® isn’t going anywhere anytime soon. Medunik USA Holds the Line So, picture yourself in the shoes of a patient battling a rare urea cycle...

Continue Reading

Top 5 Most Recently Viewed Articles

Eupraxia Pharmaceuticals: Innovating Drug Delivery in Healthcare

Updated Category News Views 179

Upcoming Conferences for Eupraxia Pharmaceuticals Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX), a cutting-edge clinical-stage biotechnology company, is making waves in the industry with its proprietary DiffuSphere™ innovation. This unique technology is designed to optimize the local delivery of medications for conditions where conventional treatments have fallen short....

Continue Reading
Supreme Court's Ruling on Giglia Lists: A Call for Justice

Updated Category News Views 105

Supreme Court's Ruling on Giglio Lists: A Call for Justice The National Police Association (NPA) has made an important move by submitting an amicus curiae brief to the U.S. Supreme Court. This brief supports Captain Manuel Adams, Jr., a dedicated law enforcement officer who is fighting against his inclusion on what’s referred to as a "Giglio list." These lists function...

Continue Reading
Analyzing Recent Trends in Zimmer Biomet Holdings' Short Interest

Updated Category News Views 179

Understanding Zimmer Biomet Holdings' Short Interest Dynamics Zimmer Biomet Holdings (NYSE: ZBH) has recently experienced a noticeable increase in its short interest, which has risen substantially by 15.79% since the last report. This change indicates that traders are selling a larger number of shares short, with a current total of 6.71 million shares sold short. This...

Continue Reading
Innovative 36-Channel LED Driver Unleashed by Diodes Incorporated

Updated Category News Views 208

Revolutionary LED Driver for the Automotive Industry Diodes Incorporated (Nasdaq: DIOD) has unveiled a state-of-the-art 36-channel linear LED current driver engineered to meet the stringent requirements of the automotive sector. This innovative component, known as the AL5887Q, presents a remarkable solution for original equipment manufacturers (OEMs) seeking to enhance...

Continue Reading
Midea Unveils Innovative Heat Pump Water Heater for Homes

Updated Category News Views 492

Midea's Breakthrough in Energy Efficiency Midea has recently taken a remarkable step towards sustainability by launching a new heat pump water heater that promises exceptional energy efficiency and performance. This innovative appliance addresses the growing need for eco-friendly home products, moving us away from older, more energy-intensive water heating methods....

Continue Reading